ESR1 and neoplasm: The tendency of ESR1 resistance mutations to appear at any time under the selective pressure of therapy, and their polyclonal nature necessitates a monitoring approach that is sensitive enough to detect them as early as possible, and in a way that tumor heterogeneity can be captured in the case of multiple metastases.